Research and Development: Comparing Key Metrics for Axsome Therapeutics, Inc. and TG Therapeutics, Inc.

Biotech Giants: R&D Spending Trends Over a Decade

__timestampAxsome Therapeutics, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 2014427920031354781
Thursday, January 1, 2015677698743445817
Friday, January 1, 20162119986066489820
Sunday, January 1, 20171995761696886134
Monday, January 1, 201823495055153793000
Tuesday, January 1, 201953647067148369000
Wednesday, January 1, 202070244579151934000
Friday, January 1, 202158060725198532000
Saturday, January 1, 202257947447112128000
Sunday, January 1, 20239794400076192000
Monday, January 1, 2024187077000
Loading chart...

Unleashing insights

A Decade of Innovation: R&D Spending in Biotech

Axsome Therapeutics vs. TG Therapeutics

In the ever-evolving world of biotechnology, research and development (R&D) are the lifeblood of innovation. Over the past decade, Axsome Therapeutics, Inc. and TG Therapeutics, Inc. have been at the forefront, investing heavily in R&D to bring groundbreaking therapies to market. From 2014 to 2023, TG Therapeutics consistently outpaced Axsome in R&D spending, peaking in 2021 with nearly double the investment compared to Axsome. However, Axsome's R&D expenses surged by over 100% in 2023, closing the gap significantly. This trend highlights Axsome's aggressive push towards innovation, while TG Therapeutics maintains a steady commitment to research. As these companies continue to invest in R&D, the biotech industry can expect a wave of new treatments and therapies, promising a brighter future for patients worldwide.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025